Nausea and Vomiting. Nausea and vomiting
Conditions
Interventions
Intervention 1: Intervention group: Olanzapine: 5mg Oral Olanzapine daily in 3 days. Intervention 2: Intervention group: Aprepitant: Kytril tablet 2mg+125mg oral Aprepitant on day one,80mg in second a
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Informed consent Receiving chemotherapy regimens with moderate and high nausea and vomiting Serum Creatinine 2 or less AST and ALT less than 3 times of normal upper limit Absolute Neutrophil counts of more than 1500 cubic millimeters Not having another cause for nausea and vomiting, such as brain tumors and stomach cancer
Exclusion criteria
Exclusion criteria: Having nausea and vomiting too much and uncontrollable Having allergies or showing other side effects of medications Pregnant and lactating women Having chronic illnesses such as: severe heart failure, uncontrolled diabetes, cardiac arrhythmia and cardiac infarction over the past 6 months Use of other interventions or confusing drugs (Quinolones, abdominal radiotherapy, other underlying conditions, etc.) Treatment with other antipsychotic drugs (Risperidone, Quetiapine, Clozapine, Phenothiazine) 30 days before entering the study Having known problem in the CNS (cerebral metastasis or seizure) or cognitive impairment Having nausea and vomiting 24 hours before treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nausea and vomiting. Timepoint: First day and 48 to 72 hours after chemotherapy. Method of measurement: The patients will be monitored for nausea and vomiting on the first day and 48 to 72 hours after chemotherapy, and their clinical data will be recorded by the information form. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarnoush Tajbakhsh
Zahedan University of Medical Sciences
Outcome results
None listed